Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 31,320,000 shares, a decrease of 6.6% from the December 15th total of 33,550,000 shares. Based on an average trading volume of 2,630,000 shares, the days-to-cover ratio is presently 11.9 days. Approximately 29.6% of the company’s shares are short sold.
Insider Buying and Selling at Allogene Therapeutics
In related news, Director Deborah M. Messemer sold 18,640 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $2.70, for a total transaction of $50,328.00. Following the completion of the sale, the director now owns 62,456 shares of the company’s stock, valued at $168,631.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 27.40% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in ALLO. EP Wealth Advisors LLC purchased a new position in Allogene Therapeutics during the third quarter valued at approximately $34,000. GTS Securities LLC purchased a new stake in shares of Allogene Therapeutics during the 3rd quarter valued at $35,000. Victory Capital Management Inc. bought a new position in Allogene Therapeutics in the third quarter valued at $37,000. Dorsey & Whitney Trust CO LLC bought a new stake in Allogene Therapeutics during the third quarter worth about $39,000. Finally, Great West Life Assurance Co. Can increased its position in shares of Allogene Therapeutics by 26.1% during the 1st quarter. Great West Life Assurance Co. Can now owns 8,827 shares of the company’s stock valued at $43,000 after purchasing an additional 1,826 shares during the last quarter. Institutional investors own 78.51% of the company’s stock.
Allogene Therapeutics Stock Up 0.6 %
NASDAQ ALLO opened at $3.15 on Thursday. The company has a market cap of $530.08 million, a PE ratio of -1.41 and a beta of 0.76. The firm’s 50-day simple moving average is $2.85 and its two-hundred day simple moving average is $3.58. Allogene Therapeutics has a 52 week low of $2.23 and a 52 week high of $8.44.
Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.16. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.05 million. Allogene Therapeutics had a negative net margin of 178,954.28% and a negative return on equity of 54.03%. As a group, equities research analysts anticipate that Allogene Therapeutics will post -2.06 EPS for the current year.
Wall Street Analysts Forecast Growth
ALLO has been the topic of a number of research analyst reports. JPMorgan Chase & Co. cut their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research report on Monday, September 25th. HC Wainwright cut their price objective on shares of Allogene Therapeutics from $23.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday, November 15th. Citigroup started coverage on shares of Allogene Therapeutics in a research report on Friday, December 8th. They set a “buy” rating and a $7.00 price target on the stock. Guggenheim downgraded Allogene Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, January 5th. Finally, JMP Securities restated a “market perform” rating on shares of Allogene Therapeutics in a research note on Friday, January 5th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $15.46.
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.